Literature DB >> 19251651

(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway.

Christine A Pratilas1, Barry S Taylor, Qing Ye, Agnes Viale, Chris Sander, David B Solit, Neal Rosen.   

Abstract

Tumors with mutant BRAF and those with receptor tyrosine kinase (RTK) activation have similar levels of phosphorylated ERK, but only the former depend on ERK signaling for proliferation. The mitogen-activated protein kinase, extracellular signal-regulated kinase kinase (MEK)/ERK-dependent transcriptional output was defined as the genes whose expression changes significantly 8 h after MEK inhibition. In (V600E)BRAF cells, this output is comprised of 52 genes, including transcription factors that regulate transformation and members of the dual specificity phosphatase and Sprouty gene families, feedback inhibitors of ERK signaling. No such genes were identified in RTK tumor cells, suggesting that ERK pathway signaling output is selectively activated in BRAF mutant tumors. We find that RAF signaling is feedback down-regulated in RTK cells, but is insensitive to this feedback in BRAF mutant tumors. Physiologic feedback inhibition of RAF/MEK signaling down-regulates ERK output in RTK cells; evasion of this feedback in mutant BRAF cells is associated with increased transcriptional output and MEK/ERK-dependent transformation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19251651      PMCID: PMC2649208          DOI: 10.1073/pnas.0900780106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Molecular interaction maps of bioregulatory networks: a general rubric for systems biology.

Authors:  Kurt W Kohn; Mirit I Aladjem; John N Weinstein; Yves Pommier
Journal:  Mol Biol Cell       Date:  2005-11-02       Impact factor: 4.138

2.  The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease.

Authors:  Justin Lamb; Emily D Crawford; David Peck; Joshua W Modell; Irene C Blat; Matthew J Wrobel; Jim Lerner; Jean-Philippe Brunet; Aravind Subramanian; Kenneth N Ross; Michael Reich; Haley Hieronymus; Guo Wei; Scott A Armstrong; Stephen J Haggarty; Paul A Clemons; Ru Wei; Steven A Carr; Eric S Lander; Todd R Golub
Journal:  Science       Date:  2006-09-29       Impact factor: 47.728

3.  A module of negative feedback regulators defines growth factor signaling.

Authors:  Ido Amit; Ami Citri; Tal Shay; Yiling Lu; Menachem Katz; Fan Zhang; Gabi Tarcic; Doris Siwak; John Lahad; Jasmine Jacob-Hirsch; Ninette Amariglio; Nora Vaisman; Eran Segal; Gideon Rechavi; Uri Alon; Gordon B Mills; Eytan Domany; Yosef Yarden
Journal:  Nat Genet       Date:  2007-02-25       Impact factor: 38.330

4.  BRAF mutation predicts sensitivity to MEK inhibition.

Authors:  David B Solit; Levi A Garraway; Christine A Pratilas; Ayana Sawai; Gad Getz; Andrea Basso; Qing Ye; Jose M Lobo; Yuhong She; Iman Osman; Todd R Golub; Judith Sebolt-Leopold; William R Sellers; Neal Rosen
Journal:  Nature       Date:  2005-11-06       Impact factor: 49.962

5.  Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.

Authors:  Keith S Hoek; Natalie C Schlegel; Patricia Brafford; Antje Sucker; Selma Ugurel; Rajiv Kumar; Barbara L Weber; Katherine L Nathanson; David J Phillips; Meenhard Herlyn; Dirk Schadendorf; Reinhard Dummer
Journal:  Pigment Cell Res       Date:  2006-08

Review 6.  Untangling the ErbB signalling network.

Authors:  Y Yarden; M X Sliwkowski
Journal:  Nat Rev Mol Cell Biol       Date:  2001-02       Impact factor: 94.444

Review 7.  Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases.

Authors:  D M Owens; S M Keyse
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

8.  Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.

Authors:  Hedwig Sutterlüty; Christoph-Erik Mayer; Ulrike Setinek; Johannes Attems; Slav Ovtcharov; Mario Mikula; Wolfgang Mikulits; Michael Micksche; Walter Berger
Journal:  Mol Cancer Res       Date:  2007-05       Impact factor: 5.852

9.  Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

Authors:  Alex A Adjei; Roger B Cohen; Wilbur Franklin; Clive Morris; David Wilson; Julian R Molina; Lorelei J Hanson; Lia Gore; Laura Chow; Stephen Leong; Lara Maloney; Gilad Gordon; Heidi Simmons; Allison Marlow; Kevin Litwiler; Suzy Brown; Gregory Poch; Katie Kane; Jerry Haney; S Gail Eckhardt
Journal:  J Clin Oncol       Date:  2008-04-07       Impact factor: 44.544

10.  PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathways.

Authors:  Huaiyu Mi; Nan Guo; Anish Kejariwal; Paul D Thomas
Journal:  Nucleic Acids Res       Date:  2006-11-27       Impact factor: 16.971

View more
  289 in total

1.  Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.

Authors:  Rita Andraos; Zhiyan Qian; Débora Bonenfant; Joëlle Rubert; Eric Vangrevelinghe; Clemens Scheufler; Fanny Marque; Catherine H Régnier; Alain De Pover; Hugues Ryckelynck; Neha Bhagwat; Priya Koppikar; Aviva Goel; Lorenza Wyder; Gisele Tavares; Fabienne Baffert; Carole Pissot-Soldermann; Paul W Manley; Christoph Gaul; Hans Voshol; Ross L Levine; William R Sellers; Francesco Hofmann; Thomas Radimerski
Journal:  Cancer Discov       Date:  2012-05-03       Impact factor: 39.397

Review 2.  RAS-targeted therapies: is the undruggable drugged?

Authors:  Amanda R Moore; Scott C Rosenberg; Frank McCormick; Shiva Malek
Journal:  Nat Rev Drug Discov       Date:  2020-06-11       Impact factor: 84.694

Review 3.  KRAS as a Therapeutic Target.

Authors:  Frank McCormick
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

4.  Transducin β-like protein 1 recruits nuclear factor κB to the target gene promoter for transcriptional activation.

Authors:  Sivakumar Ramadoss; Jiong Li; Xiangming Ding; Khalid Al Hezaimi; Cun-Yu Wang
Journal:  Mol Cell Biol       Date:  2010-12-28       Impact factor: 4.272

Review 5.  Inhibition of Ras for cancer treatment: the search continues.

Authors:  Antonio T Baines; Dapeng Xu; Channing J Der
Journal:  Future Med Chem       Date:  2011-10       Impact factor: 3.808

6.  Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signaling.

Authors:  You-Take Oh; Ping Yue; Wei Zhou; Justin M Balko; Esther P Black; Taofeek K Owonikoko; Fadlo R Khuri; Shi-Yong Sun
Journal:  J Biol Chem       Date:  2011-11-07       Impact factor: 5.157

7.  Clinical and therapeutic implications of Sprouty2 feedback dysregulation in BRAF V600E-mutation-positive papillary thyroid cancer.

Authors:  Linda A Dultz; Shumon Dhar; Jennifer B Ogilvie; Keith S Heller; Dafna Bar-Sagi; Kepal N Patel
Journal:  Surgery       Date:  2013-10-02       Impact factor: 3.982

8.  Low inducible expression of p21Cip1 confers resistance to paclitaxel in BRAF mutant melanoma cells with acquired resistance to BRAF inhibitor.

Authors:  Gun-Hee Jang; Na-Yeon Kim; Michael Lee
Journal:  Mol Cell Biochem       Date:  2015-04-26       Impact factor: 3.396

9.  Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine.

Authors:  James Nagarajah; Mina Le; Jeffrey A Knauf; Giuseppe Ferrandino; Cristina Montero-Conde; Nagavarakishore Pillarsetty; Alexander Bolaender; Christopher Irwin; Gnana Prakasam Krishnamoorthy; Mahesh Saqcena; Steven M Larson; Alan L Ho; Venkatraman Seshan; Nobuya Ishii; Nancy Carrasco; Neal Rosen; Wolfgang A Weber; James A Fagin
Journal:  J Clin Invest       Date:  2016-09-26       Impact factor: 14.808

10.  MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.

Authors:  Walter J Jessen; Shyra J Miller; Edwin Jousma; Jianqiang Wu; Tilat A Rizvi; Meghan E Brundage; David Eaves; Brigitte Widemann; Mi-Ok Kim; Eva Dombi; Jessica Sabo; Atira Hardiman Dudley; Michiko Niwa-Kawakita; Grier P Page; Marco Giovannini; Bruce J Aronow; Timothy P Cripe; Nancy Ratner
Journal:  J Clin Invest       Date:  2012-12-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.